Behaviors surrounding oral sex may increase HPV-Related cancer risk

January 14, 2021

A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. These findings add nuance to the connection between oral sex and oropharyngeal cancer -- tumors that occur in the mouth and throat -- and could help inform research and public health efforts aimed at preventing this disease.

The findings were reported Jan. 11 in the journal Cancer.

In the early 1980s,
researchers realized that nearly all cervical cancer is caused by the human papillomavirus (HPV), a DNA virus from the Papillomaviridae family. Although about 90% of HPV infections cause no symptoms and resolve within two years, a minority of people retain the virus, which can damage DNA and trigger malignancies. Nearly two decades after uncovering this link, scientists discovered that a growing number of oropharyngeal cancers are also caused by HPV. Now, the majority of oropharyngeal cancers are HPV-related.

Early research suggested that the higher a person's number of oral sex partners over a lifetime, the greater their risk of HPV-related oropharyngeal cancer. However, says Virginia Drake, M.D., first author of the study and a surgical resident at the Johns Hopkins Kimmel Cancer Center, little was known about what other risk factors might contribute to this disease.

"Although we know that HPV-related oropharyngeal cancer is strongly associated with oral sex and the number of oral sex partners," she says, "we haven't really looked at what other behaviors might contribute to this disease."

To answer this question, Drake and her colleagues worked with data from 163 patients with HPV-associated oropharyngeal cancer who were enrolled in the Papillomavirus Role in Oral Cancer Viral Etiology (PROVE) study and 345 healthy people with demographic characteristics similar to those of the study participants. The study ran from 2013 to 2018 at the Johns Hopkins Kimmel Cancer Center, the University of California San Francisco Helen Diller Family Comprehensive Cancer Center and the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai.

Each of these volunteers -- patients with cancer and healthy controls -- took the same detailed behavioral survey on lifetime and recent sexual behaviors, including number of partners, age of sexual initiation, type and order of sexual acts, partner dynamics and extramarital sex. They also submitted a blood sample to test for antibodies to strains of HPV and tumor samples from the patients with cancer to confirm presence of the virus.

When the researchers compared data from the patients who had cancer with data from the healthy controls, they found several key differences. For example, although the researchers confirmed that a higher number of lifetime oral sex partners increased the risk of HPV-related oropharyngeal cancer, they also found higher risk was linked to an earlier age of having oral sex (under 18), higher oral sex "intensity" (more sex partners over a shorter time) and having oral sex before other kinds of sex.

The research team, which included Gypsyamber D'Souza, Ph.D., professor of epidemiology and international health at the Johns Hopkins Bloomberg School of Public Health with a joint appointment in oncology and otolaryngology-head and neck surgery, also found that relationship dynamics and partner behavior can affect risk. For example, a higher number of casual sex partners, extramarital sex and suspicion that a partner had extramarital sex also significantly raised the risk of HPV-associated oropharyngeal cancer, by more than 1.6 times. Having a sexual partner who was at least 10 years older when the study participant was younger than age 23 was also associated with diagnosis of disease.

Those with cancer universally tested positive for serum antibodies to HPV oncogenes. And risk of HPV-related oropharyngeal cancer was significantly higher for volunteers who were positive for more distinct HPV strains.

Together, Drake explains, these findings add context to which behaviors might affect the risk of this disease. They also could inform future research on how HPV-related oropharyngeal cancers develop -- regarding questions such as whether people have a more robust immune response to HPV, and therefore a lower risk of cancer, if their first HPV exposure is to genital HPV (before they are exposed to oral HPV) or if they are exposed at older ages.

"Our biggest goal was to add context to what we already know about these cancers and gain a better understanding of the complex nature of this disease," Drake says. "This contemporary look into HPV-related oropharyngeal risk factors allows us to do just that."
-end-
Other Johns Hopkins researchers who contributed to this study are Carole Fakhry, Melina Windon, Matthew Stewart, Lee Akst, Alexander Hillel, Wade Chien, Christine Gourin, Rajarsi Mandal, Wojtek Mydlarz, Lisa Rooper, Tanya Troy, Siddhartha Yavvari and David Eisele.

This study was supported by the National Institute of Dental and Craniofacial Research (grant P50 DE019032) and the National Institute on Deafness and Other Communication Disorders (grant 1K23DC014758).

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.